Effect of magnesium sulfate in acute ischemic stroke

Evaluation of the effect of intravenous magnesium sulfate in improvement of disability resulted from acute ischemic stroke in patients referred to Ahvaz Golestan hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015060712781N4

Enrollment

120

Registered

2016-04-03

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: occlusion of middle cerebral artery. Condition 2: disability of cerebral infarction. Occlusion and stenosis of middle cerebral artery Sequelae of cerebral infarction

Interventions

Intervention 1: Intervention: Magnesium sulfate vial 4 gram in 200cc normal saline loading dose in 20 minutes intravenous infusion then 16 gram in 800cc normal saline maintenance dose intravenous infu

Treatment - Drugs

Intervention: Magnesium sulfate vial 4 gram in 200cc normal saline loading dose in 20 minutes intravenous infusion then 16 gram in 800cc normal saline maintenance dose intravenous infusion during 24 h

Placebo: Serum normal saline 800cc intravenous infusion during 24 hours till 5 days

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with the following conditions were included: 45 to 75 years old patients with ischemic stroke within the middle cerebral artery; patients who had symptoms of focal neurological deficits on arrival; ischemic stroke had occurred within past 24 hours; Modified National Institutes of Health Stroke Scale was between 5 to 25 on arrival; no evidence of a brain hemorrhage in primary CT scan. Exclusion criteria: patients with the following conditions were excluded: prior chronic renal failure or serum Creatinine level above 3 mg/dl; pregnancy; prior heart block or its evidences in initial ECG; prior respiratory failure or oxygen saturation below 90% or respiratory rate below 12 or above 24 per minute; prior neurodegenerative, demyelinating, muscular diseases and brain tumor; acute metabolic disorder (magnesium, sodium and potassium level); life-threatening diseases which may lead to death in the next three months; and patients who need help in daily activities and walking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disability of acute ischemic stroke. Timepoint: Before intervention.1 month and 3 month after intervention. Method of measurement: mRankin Scale Score and mNIHSS score.	—

Secondary

Measure	Time frame
Serum level of magnesium sulfate. Timepoint: Before intervention and the last day of intervention. Method of measurement: Blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavood Kashipazha

Ahvaz Jundishapur University of Medical Scienses

dakashi47@gmail.com+98 61 3374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026